Survodutide Dosing: 4.8mg/Week for Fat Loss

Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim. In Phase 2 trials, participants receiving 4.8mg weekly lost up to 18.7% of body weight over 46 weeks — with the glucagon component adding thermogenic fat-burning effects that GLP-1-only drugs lack.

Survodutide is not FDA-approved. It is currently in Phase 3 clinical trials. Everything below reflects published clinical trial data and is not medical advice.

Quick Reference: Clinical Trial Dosing

For the full survodutide peptide profile and vendor pricing, see our Survodutide peptide page.

Titration Schedule

The Phase 2 trial used a gradual dose escalation to minimize GI side effects. Each dose level was maintained for approximately 4 weeks before increasing:

Key point: Participants who couldn't tolerate a dose increase could remain at their current level or reduce. In the Phase 2 trial, not all participants reached 4.8mg — the "actual doses received" analysis showed 18.7% weight loss at 4.8mg, while the "planned treatment" (intention-to-treat) analysis showed 14.9%.

Dose Groups in Phase 2

The Phase 2 trial tested four dose levels against placebo:

The difference between "planned" and "actual" analyses at 4.8mg is significant — participants who tolerated the full dose and stayed on it achieved substantially greater weight loss.

Routes of Administration

Subcutaneous Injection (Only Route)

Survodutide is a peptide that requires injection — it cannot be taken orally.

• Sites: Abdomen, thigh, or upper arm
• Volume: Small injection volume with insulin syringe
• Rotation: Rotate injection sites weekly
• Timing: Same day each week, any time of day

Reconstitution Quick Reference

If using research-grade lyophilized survodutide:

For the full reconstitution walkthrough with dilution charts, see our Survodutide Reconstitution Guide.

Mechanism of Action

Survodutide's dual mechanism creates complementary metabolic effects:

GLP-1 receptor activation — Suppresses appetite, slows gastric emptying, improves insulin sensitivity. The same pathway targeted by semaglutide.

Glucagon receptor activation — Increases energy expenditure through thermogenesis, promotes hepatic fat oxidation, and reduces liver fat. This is what differentiates survodutide from GLP-1-only drugs.

The combination means weight loss comes from both reduced caloric intake (GLP-1) and increased caloric expenditure (glucagon). In the Phase 2 T2D trial, survodutide at doses ≥1.8mg weekly produced greater body weight reductions than semaglutide 1mg.

Injection Timing & Sites

• When: Same day each week, at any consistent time
• Where: Rotate between abdomen (2 inches from navel), thigh (front or outer), and upper arm
• Fasting: Not required, but some prefer morning injection on an empty stomach
• Missed dose: If within 3 days of scheduled dose, take it. If more than 3 days late, skip and resume on the next scheduled day.

Side Effects & Safety

Survodutide's side effect profile is consistent with the GLP-1 agonist class, with the glucagon component adding some nuances.

Common Side Effects (Phase 2 Data)

Gastrointestinal effects dominated, occurring in 75% of survodutide recipients vs 42% of placebo:

• Nausea — Most common, typically worst during dose escalation
• Vomiting — More common at higher doses
• Diarrhea — Dose-dependent
• Constipation — Less frequent than with some GLP-1-only drugs
• Decreased appetite — Expected pharmacological effect

Safety Signals to Monitor

• Heart rate: Small increases observed, consistent with GLP-1 agonist class
• Hepatic effects: Monitor liver enzymes (ALT/AST) — glucagon receptor activation affects liver metabolism
• Pancreatic safety: Lipase and amylase monitoring recommended, as with all GLP-1 agonists
• Thyroid: GLP-1 agonists carry a class warning for thyroid C-cell tumors in rodents

Adverse Event Rates

In the Phase 2 obesity trial, adverse events occurred in 91% of survodutide recipients vs 75% of placebo. Most were mild-to-moderate GI effects. Serious adverse events were similar between groups.

How Survodutide Compares

Survodutide occupies a unique position: it's the only pure GLP-1/glucagon dual agonist in late-stage development. Retatrutide adds GIP as a third target but is also investigational. For current FDA-approved options, see our semaglutide and tirzepatide pages.

Frequently Asked Questions

What is the standard survodutide dose for weight loss?

In the Phase 2 clinical trial, the highest dose group received 4.8mg once weekly after a gradual titration over approximately 20 weeks. This produced up to 18.7% body weight loss at 46 weeks. Survodutide is not FDA-approved and all dosing reflects clinical trial protocols.

How often is survodutide injected?

Survodutide is administered as a once-weekly subcutaneous injection, taken on the same day each week. This is similar to semaglutide's dosing frequency.

Why does survodutide require such a long titration?

The 20-week dose escalation (0.3mg → 0.6mg → 1.2mg → 1.8mg → 2.7mg → 3.6mg → 4.8mg) minimizes gastrointestinal side effects. GLP-1/glucagon dual agonists cause significant nausea when started at high doses. Slow titration allows the body to adapt.

Is survodutide FDA-approved?

No. Survodutide is currently in Phase 3 clinical trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) by Boehringer Ingelheim. All dosing information comes from published clinical trial data, not established medical protocols.

How does survodutide compare to semaglutide?

Survodutide is a dual GLP-1/glucagon receptor agonist, while semaglutide targets only GLP-1. The glucagon component adds energy expenditure and hepatic fat oxidation. Phase 2 data showed survodutide at higher doses produced greater weight loss than semaglutide 1mg in the T2D trial.

Related Reading

• Survodutide Benefits: 6 Effects You Should Know — research-backed benefits ranked by evidence
• Survodutide Reconstitution Guide — step-by-step mixing and dilution charts
• Survodutide Bloodwork Guide — what labs to track and optimal ranges
• Retatrutide Dosing Guide — triple agonist comparison
• Semaglutide Dosing Guide — the leading GLP-1 agonist
• Tirzepatide Dosing Guide — dual GIP/GLP-1 agonist
• Calculate Your Survodutide Cycle Cost — estimate vials needed and total cost

References

This article is for educational and informational purposes only. It is not medical advice and should not be used to diagnose, treat, or prevent any condition. Survodutide is an investigational compound not approved by the FDA for any indication. Consult a licensed healthcare provider before using any peptide.